CBR Systems, Inc.

Banking newborn stem cells an option for couples choosing gestational carrier TRUMBULL, Conn., July 27, 2023 /PRNewswire/ -- CooperSurgical, a global leader in fertility and women's health, announced that Chrissy Teigen, mom, New York Times best-selling cookbook author, television host and entrepreneur, selected Cord Blood Registry® (CBR®) to bank the umbilical cord blood and cord tissue of her newborn, Wren Alexander Stephens, who was born via gestational carrier in June. "Expectant parents may be confused if they can preserve their newborn's stem cells when they are using a surrogate or gestational carrier. The process of collecting and storing cord blood and cord tissue is no different for parents who are growing their families through use of a gestational carrier versus a pregnancy carried by the intended parent," stated board-certified OB/GYN and CBR spokesperson, Dr. Christine Sterling. "As Chrissy's example demonstrates, the option to bank cord blood and tissue is still very much available to parents who build their families in a wide variety of ways." CBR and Teigen launched an educational campaign earlier this year to raise awareness about the potential benefits of banking newborn stem cells from cord blood and cord tissue. CBR is the largest family newborn stem cell preservation company in the world, helping parents store newborn stem cells from cord blood and cord tissue for their children. CBR is the #1 choice for parents1 and the most recommended cord blood preservation company by OB/GYNs.2 "CBR is dedicated to educating families about the life-saving potential of newborn stem cells, helping to provide them with access to current treatments and future clinical therapies," stated Holly Sheffield, President, CooperSurgical. "We are delighted that our campaign is educating more families that newborn stem cell preservation is a viable option when using a gestational carrier, and we are proud to continue working with Chrissy over the next several months." For more information about CBR and the benefits of cord blood banking, please visit . About CBR by CooperSurgical Cord Blood Registry® (CBR®) is the largest family newborn stem cell preservation company in the world, helping parents store stem cells from cord blood and cord tissue for their children. Founded in 1994, CBR is the #1 choice for parents1 and most recommended by OB/GYNs for newborn stem cell preservation.2 The company has released over 700 samples intended for use in transplant medicine and regulated investigational regenerative medicine applications. CBR is here to help expand the possibilities of what newborn stem cell therapies can do for families and give parents the confidence to Bank on CBR™. More information can be found at . About CooperSurgical CooperSurgical® is a leading fertility and women's healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most in life. CooperSurgical is at the forefront of delivering innovative assisted reproductive technology and genomic solutions that enhance the work of ART professionals to the benefit of families. We currently offer over 600 clinically relevant medical devices to women's healthcare providers, including testing and treatment options. CooperSurgical is a wholly-owned subsidiary of CooperCompanies (NYSE: COO). CooperSurgical, headquartered in Trumbull, CT, produces and markets a wide array of products and services for use by women's health care clinicians. More information can be found at . About CooperCompanies CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE: COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of more than 15,000 with products sold in over 130 countries. For more information, please visit . Disclaimer: The use of cord blood is determined by the treating physician and is influenced by many factors, including the patient's medical condition, the characteristics of the sample, and whether the cord blood should come from the patient or an appropriately matched donor. Cord blood has established uses in transplant medicine; however, its use in regenerative medicine is still being researched. There is no guarantee that potential medical applications being studied in the laboratory or clinical trials will become available. Cord tissue use is still in early research stages, and there is no guarantee that treatments using cord tissue will be available in the future. Cord tissue is stored whole. Additional processing prior to use will be required to extract and prepare any of the multiple cell types from cryopreserved cord tissue. Cbr Systems, Inc.'s activities for New York State residents are limited to collection of umbilical cord tissue and long-term storage of umbilical cord–derived stem cells. Cbr Systems, Inc.'s possession of a New York State license for such collection and long-term storage does not indicate approval or endorsement of possible future uses or future suitability of these cells. References: Internal source. Data on file. Blind survey, Egg Strategy, 10/19, funded by CBR. Contact: CooperSurgical EvolveMKD [email protected] SOURCE CooperSurgical®

Educational campaign will highlight why parents should Bank on CBR™ TRUMBULL, Conn., Feb. 8, 2023 /PRNewswire/ -- CooperSurgical®, a global leader in fertility and women's health, announced Chrissy Teigen, mom, New York Times best-selling cookbook author, television host and entrepreneur, has partnered with Cord Blood Registry® (CBR®) on an educational campaign focused on the benefits of banking newborn stem cells from cord blood and cord tissue, which is launching today. Experience the full interactive Multichannel News Release here: Continue Reading Chrissy Teigen Partners with Cord Blood Registry® Chrissy Teigen Partners with Cord Blood Registry® "As part of my pregnancy, I learned banking my baby's newborn stem cells gives us access to current treatments and future clinical therapies, if my child ever needs them. We knew this was something we wanted to do – as a mom, I want to make sure our children have every possible option available to them," stated Ms. Teigen. "I was confident in partnering with CBR, as they are the #1 choice for parents and the most recommended cord blood preservation company by OB/GYNs." This new, multichannel direct-to-consumer campaign, featuring Ms. Teigen will include content across digital and social media as well as national and regional earned media. The campaign will also highlight the real-life impact banked newborn stem cells from cord blood and cord tissue has had on patient lives and physician practices. These powerful cells have the natural ability to turn into other types of important cells. Emerging research in regenerative medicine is examining the ability of newborn stem cells to also help repair and regenerate damaged cells with healthy ones. In fact, 85% of the cord blood released for families was with the intention to be used for regenerative medicine purposes. "When we were identifying campaign partners, Ms. Teigen was the obvious choice. Her openness about successes and challenges spanning her business and personal life is relatable to expectant parents across the United States," stated Holly Sheffield, President, CooperSurgical. "CBR is the largest newborn stem cell preservation company in the world, helping parents store newborn stem cells from cord blood and cord tissue for their children. We are excited to educate more parents about the possibilities that storing newborn stem cells could have for their family's future." To learn more about CBR and the campaign featuring Ms. Teigen, please visit . About CBR by CooperSurgical Cord Blood Registry® (CBR®) is the largest family newborn stem cell preservation company in the world, helping parents store stem cells from cord blood and cord tissue for their children. Founded in 1994, CBR is the #1 choice for parents and most recommended by OB/GYNs for newborn stem cell preservation. The company has released over 700 samples intended for use in transplant medicine and regulated investigational regenerative medicine applications. CBR is here to help expand the possibilities of what newborn stem cell therapies can do for families and give parents the confidence to Bank on CBRÔ. More information can be found at . About CooperSurgical CooperSurgical is a leading fertility and women's healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most in life. CooperSurgical is at the forefront of delivering innovative assisted reproductive technology and genomic solutions that enhance the work of ART professionals to the benefit of families. We currently offer over 600 clinically relevant medical devices to women's healthcare providers, including testing and treatment options. CooperSurgical is a wholly-owned subsidiary of CooperCompanies (NYSE: COO). CooperSurgical, headquartered in Trumbull, CT, produces and markets a wide array of products and services for use by women's health care clinicians. More information can be found at . About CooperCompanies CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, CA, Cooper has a workforce of more than 14,000 with products sold in over 100 countries. For more information, please visit . Contact: CooperSurgical EvolveMKD [email protected] SOURCE CooperSurgical®

Research Study Will Collect Information Directly From Patients' Electronic Health Records to Help Researchers and Clinicians Better Understand Duchenne and Becker Muscular Dystrophy WASHINGTON, Dec. 6, 2022 /PRNewswire/ -- Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), today announced the launch of the organization's Electronic Health Record (EHR) Study with the first patients consented to participate. PPMD's EHR Study will extract data from several of the organization's Certified Duchenne Care Centers (CDCCs) across the country to collect clinical data to inform research and care without adding additional burden on patients and families. Arkansas Children's Hospital is the first CDCC to participate, with several more CDCCs in the process of joining PPMD's EHR Study later this year. As part of the study, data from consented patients' health records will be securely sent to PPMD's Duchenne Outcomes Research Interchange ('the Interchange'), a patient- and clinician-reported data warehouse which can combine EHR data with data from The Duchenne Registry, as well as data provided by industry partners with approved therapies. "For the last several years, PPMD has been expanding and enhancing The Duchenne Registry, our comprehensive patient-reported outcomes (PRO) registry for Duchenne and Becker muscular dystrophy. As a new therapeutic landscape emerged, we saw a clear need to combine PRO data with clinician-reported outcomes data. Recent advances in technology around shared data have enabled PPMD to combine these data sets within a centralized data interchange that will benefit the entire community – from patients, to clinicians and scientists exploring therapeutics and treatments. PPMD's Interchange provides this central repository for all types of Duchenne and Becker data and 'real world evidence' to be collected and analyzed," said Ann Martin, MS, CGC, PPMD's Vice President of Community Research & Genetic Services. PPMD launched the Interchange in 2018 with Prometheus Research (an IQVIA company), an industry leader in health data informatics. All data is stored securely and in accordance with strict industry standards and patient privacy laws. The Interchange will only allow data to be used for research purposes and to improve care for Duchenne and Becker patients. In an effort to collect clinical data without adding additional burden on patients and families, once a patient consents to participate in PPMD's EHR Study, the study will automatically collect important information from doctor visits and send it to the Interchange. "Collecting data directly from the EHR capitalizes on recent advances in health data interoperability, positioning patient advocacy groups to gather data more easily, without asking either the clinician or the patient to enter the data themselves. It is faster and more efficient for everyone, with less possibility for errors," explains Megan Freed, MPH, PPMD's Director of Data and Technology Strategy. "As physicians treating Duchenne and Becker patients, the more information we have about this rare, multi-system disease, the more informed decisions we can make about clinical care. The ability to view in the Interchange population-level data from our clinic compared to other Duchenne and Becker clinics in the CDCC Network is incredibly valuable to advancing the science," said Dr. Aravindhan Veerapandiyan, MD, an assistant professor of Pediatrics in the University of Arkansas for Medical Sciences (UAMS) College of Medicine who practices as a child neurologist at Arkansas Children's Hospital and directs the Certified Duchenne Care Center / Dystrophinopathy Clinic for children with Duchenne and Becker muscular dystrophies. While patients do not need to be registered with The Duchenne Registry to participate in PPMD's EHR Study, the ultimate goal is to combine this data within the Interchange, building the most comprehensive dataset on Duchenne and Becker muscular dystrophy. Pat Furlong, PPMD's Founding President & CEO, explains that these data sources fit together like puzzle pieces to create a more complete picture of the natural history of the disorder: "Since a small group of parents and grandparents formed PPMD over 25 years ago, we have believed in the importance of innovation and patient data in the fight to end Duchenne. The Duchenne Registry remains a critical tool in Duchenne research, as it will always be important to get information directly from patients about how they are feeling and what they are able to do. And now, powered with 15 years of robust data thanks to our incredible community, it is ready to expand and evolve. With the addition of EHR data, PPMD's Interchange will provide a more complete picture of Duchenne and Becker, allowing researchers and clinicians to improve care and develop treatments faster." Over the coming years, PPMD will invite all CDCCs within its network to participate in the EHR Study. Patients who attend participating CDCCs will be invited to join the study during an upcoming clinic or phone visit. If the patient consents to participate, the clinic will securely push data from the EHR to the Interchange. The data will include diagnosis, medications, laboratory tests, and procedures. Retrospective data will be pushed, and all prospective data will be pushed until the study ends or the patient requests to be withdrawn from the study. To learn more about PPMD's EHR Study, click here. ABOUT PARENT PROJECT MUSCULAR DYSTROPHY: Duchenne is a fatal genetic disorder that slowly robs people of their muscle strength. Parent Project Muscular Dystrophy (PPMD) fights every single battle necessary to end Duchenne. We demand optimal care standards and ensure every family has access to expert healthcare providers, cutting edge treatments, and a community of support. We invest deeply in treatments for this generation of Duchenne patients and in research that will benefit future generations. Our advocacy efforts have secured hundreds of millions of dollars in funding and won five FDA approvals. Everything we do—and everything we have done since our founding in 1994—helps those with Duchenne live longer, stronger lives. We will not rest until we end Duchenne for every single person affected by the disease. Join our fight against Duchenne at EndDuchenne.org. Follow PPMD on Facebook, Twitter, Instagram, and YouTube. SOURCE Parent Project Muscular Dystrophy (PPMD)